Perfusion Imaging < Pergolide < Periaqueductal Gray

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 43.
[0-20] [0 - 20][0 - 43][20-40]

Ident.	Authors (with country if any)	Title
000113 (1999)	W J Weiner [États-Unis]	The initial treatment of Parkinson's disease should begin with levodopa.
000114 (1999)	J L Montastruc [France] ; O. Rascol ; J M Senard	Treatment of Parkinson's disease should begin with a dopamine agonist.
000153 (1999)	J E Ahlskog [États-Unis] ; R J Uitti ; M K O'Connor ; D M Maraganore ; J Y Matsumoto ; K F Stark ; M F Turk ; O L Burnett	The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
000297 (2000)	J. Kulisevsky [Espagne] ; C. García-Sánchez ; M L Berthier ; M. Barbanoj ; B. Pascual-Sedano ; A. Gironell ; A. Estévez-González	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
000582 (2001)	W. Koller [États-Unis] ; A. Lees ; M. Doder ; M. Hely	Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
000748 (2002)	Michele De Mari ; Angelo Zenzola ; Paolo Lamberti	Antiparkinsonian treatment in pregnancy.
000867 (2002)		DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
000871 (2002)		DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
000998 (2003)	Prithiva Navan [Royaume-Uni] ; Leslie J. Findley ; Jim A R. Jeffs ; Ronald K B. Pearce ; Peter G. Bain	Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
000C30 (2003)	Prithiva Navan [Royaume-Uni] ; Leslie J. Findley ; Jim A R. Jeffs ; Ronald K B. Pearce ; Peter G. Bain	Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
000E34 (2004)	Olivier Rascol ; Atul Pathak ; Haleh Bagheri ; Jean-Louis Montastruc	New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.
000E40 (2004)	Judit Horvath [Suisse] ; Robin D. Fross ; Galit Kleiner-Fisman ; René Lerch ; Hans Stalder ; Suzanne Liaudat ; William J. Raskoff ; Keith D. Flachsbart ; Harry Rakowski ; Jean-Claude Pache ; Pierre R. Burkhard ; Anthony E. Lang	Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
000E49 (2004)	Pinky Agarwal [États-Unis] ; Stanley Fahn ; Steven J. Frucht	Diagnosis and management of pergolide-induced fibrosis.
000F67 (2004)	Katherine Grosset [Royaume-Uni] ; Fiona Needleman ; Graeme Macphee ; Donald Grosset	Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
001077 (2004)	Reinhard Horowski ; Sven J Hnichen ; Heinz H. Pertz	Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.
001078 (2004)	K Ray Chaudhuri ; Vandena Dhawan ; Sumit Basu ; Gordon Jackson ; Per Odin	Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
001079 (2004)	Olivier Rascol ; Atul Pathak ; Haleh Bagheri ; J-L Montastruc	Dopaminagonists and fibrotic valvular heart disease: further considerations.
001106 (2005)	Katherine Grosset [Royaume-Uni] ; Donald Grosset ; Andrew Lees	Trial of subtherapeutic pergolide in de novo Parkinson's disease.
001176 (2005)	Manfred Gerlach ; Heinz Reichmann ; Peter Riederer	Levodopa in the treatment of Parkinson's disease: current controversies.
001178 (2005)	Naushad Hirani ; Charles C. Bayliff ; David G. Mccormack	Diagnosis and management of pergolide-induced fibrosis.
001217 (2005)	Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol ; Cristina Sampaio	Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Pergolide" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Pergolide" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Pergolide
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024